Newsroom

Abstract Background: An extended duration flea and tick medication of the isoxazoline class (fluralaner) was introduced in 2014 in the United States and other countries. A survey was developed in 2016 to gauge dog owner adherence with veterinary recommendations around the administration of preventive flea and tick medications. Current fluralaner-using dog owners were also asked […]

Read more

Abstract Background: Fluralaner is a potent insecticide and acaricide with rapid and persistent efficacy. This study measured the efficacy of fluralaner flavored chews (Bravecto®, Merck Animal Health) administered to dogs against adult Ctenocephalides felis felis and egg production. Methods: Twelve purpose-bred dogs were randomly allocated to two groups of six dogs each. Dogs in treatment […]

Read more

Abstract Background: The efficacy of fluralaner spot-on solution administered once topically against induced infestations with Rhipicephalus sanguineus was evaluated in dogs over a 12-week post-treatment period. Methods: Six negative-controlled studies were conducted, involving a total of 112 adult dogs (57 mixed breed, 47 Beagles, eight Labradors). In each study, dogs were randomized to two groups […]

Read more

Abstract Acaricidal (tick) and insecticidal (flea) efficacy of systemically and cutaneously distributed ectoparasiticide products for dogs are compared based on permethrin and fluralaner as representative molecules. Results of efficacy studies against fleas and ticks are reviewed that show generally good to excellent results. Both externally and systemically distributed treatments have benefits and weaknesses in potentially […]

Read more

Abstract Background: Fluralaner is a novel systemic ectoparasiticide for dogs and cats providing immediate and persistent flea- and tick-control after a single topical dose. Prescribing directions recommend waiting 72 h following topical administration before immersing dogs in water. The objective of this study was to determine whether water immersion immediately prior to treatment or earlier […]

Read more

Abstract Background: Veterinary clinic transaction records from the USA were examined to determine dog owner purchase patterns for three prescription ectoparasiticides. In-clinic purchases of formulations of fluralaner (with 12-week duration per dose) were compared with dog owner purchases of afoxolaner and spinosad (both with 4 week duration per dose) in a population of 231,565 dogs […]

Read more

Abstract Background: A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/ml) (Bravecto® Plus) has been developed to provide broad spectrum parasite protection for cats. The effectiveness and safety of this product against ticks and fleas was assessed in a randomized, controlled, 12-week study in client-owned cats in Germany and Spain. Methods: Eligible households […]

Read more

Abstract Background: Fluralaner is a potent acaricide and insecticide effective against flea and tick (F/T) infestations on dogs and cats. Fluralaner for dogs can be administered orally as a flavored chew with up to a 12-week redosing interval, about three-fold less frequently than monthly F/T medications. This study surveyed dog owners who currently administer fluralaner […]

Read more

Abstract Background: Adherence to a prescribed therapeutic regimen is a critical factor for achieving medication effectiveness and therefore treatment success. In the case of companion animal ectoparasite control, suboptimal owner adherence to medication recommendations is thought to be a common cause of treatment failure, and previous reports have found pet owners applying an average of […]

Read more